Strategic scientific consulting

Complex science.
Decisive strategy.

Precision BioStrategy helps life-sciences teams translate biomarker, laboratory, and clinical complexity into clear decisions—and executable paths from discovery to delivery.

Explore our workDiscuss a challenge

Where we create value

Clarity at the moments that matter.

Scientific programs rarely fail because teams lack data. They stall when evidence, operations, and decision-making are not aligned. We bring a scientist-operator’s perspective to the inflection points where laboratory reality must meet clinical intent.

Evidence before opinionSeparate what is known, inferred, and still uncertain.
Strategy built to executeTranslate recommendations into owners, decisions, and controls.
Senior attention throughoutFounder-led work without the handoffs of a large consultancy.

When to bring us in

A consequential decision.
A practical path forward.

For biotech leaders, diagnostic teams, and medical affairs groups facing decisions that cross scientific and operational boundaries.

Your assay strategy needs a clear direction.

You need to determine whether the evidence supports the intended use, resolve validation gaps, or plan an LDT-to-CDx transition.

Start with: an independent evidence assessment and a prioritized decision roadmap.

Your laboratory partnership is becoming difficult to govern.

Testing performance, reporting, turnaround time, or responsibilities are unclear—and the program needs a workable operating model.

Start with: a review of the workflow, commitments, metrics, and escalation process.

Your program is approaching launch.

The scientific plan is progressing, but provider workflows, laboratory readiness, and cross-functional ownership still need alignment.

Start with: a launch-readiness assessment and an actionable closure plan.

Advisory architecture

Science, systems
and delivery.

Focused engagements for rare disease, precision medicine, advanced diagnostics, and other programs where the testing strategy is central to clinical success.

01

Scientific & biomarker strategy

Turn biological rationale and clinical questions into a disciplined evidence plan.

  • Biomarker and endpoint strategy
  • Evidence-gap and risk assessment
  • Translational decision frameworks
02

Laboratory & diagnostic strategy

Connect intended use, analytical performance, clinical context, and future regulatory pathways.

  • LDT, CDx, and assay-transfer strategy
  • Validation review and laboratory selection
  • Method comparison and reference intervals
03

Launch & program leadership

Design sponsored-testing and laboratory programs that can be governed, measured, and improved.

  • Launch readiness and operating models
  • Turnaround time, SLA, and escalation design
  • Metrics, reporting, and vendor governance
04

Medical affairs enablement

Equip scientific teams to communicate complex evidence with accuracy and practical relevance.

  • Scientific narrative and insight strategy
  • KOL and investigator engagement
  • Cross-functional decision support

How we work

From ambiguity
to accountable action.

A repeatable working model, adapted to the decision—not a prepackaged consulting playbook.

01

Frame the decision

Clarify the real question, who owns it, and what a useful answer must enable.

02

Interrogate the evidence

Test assumptions, distinguish observation from interpretation, and surface risk.

03

Build the path

Convert the scientific position into a practical plan, governance model, and decision criteria.

04

Stay through execution

Support implementation, challenge drift, and refine the model as evidence changes.

Selected experience

Depth without disclosure.

Representative, anonymized experience. Client-confidential details remain confidential.

These examples describe prior leadership and advisory experience and do not identify current or former clients.

LDT → CDx

Directed the transfer of a clinically critical antibody assay into a companion-diagnostic pathway and national reference-laboratory operations.

11

Clinical protocols supported across transplant diagnostics, connecting biomarker evidence with operational study delivery.

36

Investigator-initiated studies enabled through scientific strategy, medical engagement, and research governance.

1:400

Risk-based retesting policy developed for a high-volume rare-disease screening program—balancing evidence, operations, and patient access.

Prior career leadership

Connecting an antibody assay to clinical delivery.

The challenge
A rare-disease program depended on consistent antibody testing, a reference-laboratory partnership, and an assay transition toward a companion diagnostic.
The contribution
Led assay strategy execution, coordinated the LDT-to-CDx transfer, and developed retesting policy, operational dashboards, and field training.
The result
Established a coordinated testing framework connecting assay decisions, laboratory operations, and field implementation. This experience predates Precision BioStrategy.

Precision BioStrategy advisory engagement

Making a sponsored-testing program reviewable.

The challenge
A diagnostic program needed to reconcile analytical validation, laboratory workflows, service commitments, and the reporting needed for program oversight.
The contribution
Reviewed validation evidence, consolidated scientific feedback, mapped reporting gaps, and modeled program economics to support client decisions.
The result
Delivered a consolidated external review and decision-support materials defining documentation corrections, proposed follow-up studies, and operational requirements. Laboratory resolution and launch outcomes remain pending.
Independent judgment.
Operational empathy.
Scientific rigor.

Founder-led by design

A scientist who understands the system around the science.

Precision BioStrategy is led by a PhD scientist and biotech operator whose career spans molecular biology, biomarker development, clinical research, laboratory operations, diagnostic commercialization, and field medical leadership.

That range matters. It brings laboratory detail into executive decisions—and keeps high-level strategy grounded in what laboratories, clinicians, partners, and patients actually experience.

PhD-trained scientistBiochemistry & molecular biology
Industry operatorDiagnostics, rare disease & medical affairs

PBS Insights

From evidence
to execution.

Practical perspectives for teams making consequential scientific and operational decisions.

From discovery to delivery™

Bring clarity to your next critical decision.

Tell us the decision you need to make, the stage of your program, and where the scientific or operational uncertainty sits. We can define a focused first engagement around what will move the work forward.

Start a conversation